Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-analysis

Vanessa Blumer, Rodrigo Mendirichaga, Gabriel A. Hernandez, Gerardo Zablah, Sandra Chaparro

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Continuous-flow left ventricular assist devices (CF-LVADs) decrease mortality and improve quality of life in patients with advanced heart failure (HF). Their widespread utilization has led to concerns regarding increased adverse effects, especially in women. Nevertheless, sex-specific data remain limited. We searched Medline, Embase, Scopus, and the Cochrane Library for publications reporting sex-specific outcomes after CF-LVADs from January 2008 through January 2017. Outcomes were compared under the random-effects model and heterogeneity examined via χ test and I statistics. A total of 10 studies including 4,493 CF-LVAD recipients were included in the analysis (23.5% women). The overall rate of stroke was significantly higher in women (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.32-2.84; p = 0.0007). This was true for ischemic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008) and hemorrhagic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008). Women were also more likely to develop right HF necessitating right ventricular assist device (RVAD) implantation (OR 2.12; 95% CI 1.08-4.15; p = 0.03). Other adverse events including renal failure, bleeding, and device-related infection were comparable for both genders. The overall mortality while on CF-LVAD was similar in both groups (OR 1.05; 95% CI 0.81-1.36; p = 0.71). Our analysis suggests that women are at greater risk of significant complications such as cerebrovascular events and right HF necessitating RVAD after CF-LVAD implantation. Further research is needed to better understand the mechanisms underlying these sex-specific outcome disparities.

Original languageEnglish (US)
Pages (from-to)440-449
Number of pages10
JournalASAIO journal (American Society for Artificial Internal Organs : 1992)
Volume64
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Meta-Analysis
Odds Ratio
Confidence Intervals
Heart Failure
Stroke
Mortality
Statistics
Libraries
Renal Insufficiency
Publications
Quality of Life
Hemorrhage
Equipment and Supplies
Infection

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices : A Systematic Review and Meta-analysis. / Blumer, Vanessa; Mendirichaga, Rodrigo; Hernandez, Gabriel A.; Zablah, Gerardo; Chaparro, Sandra.

In: ASAIO journal (American Society for Artificial Internal Organs : 1992), Vol. 64, No. 4, 01.07.2018, p. 440-449.

Research output: Contribution to journalArticle

@article{09e9a007b8874300b932facf4741035e,
title = "Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-analysis",
abstract = "Continuous-flow left ventricular assist devices (CF-LVADs) decrease mortality and improve quality of life in patients with advanced heart failure (HF). Their widespread utilization has led to concerns regarding increased adverse effects, especially in women. Nevertheless, sex-specific data remain limited. We searched Medline, Embase, Scopus, and the Cochrane Library for publications reporting sex-specific outcomes after CF-LVADs from January 2008 through January 2017. Outcomes were compared under the random-effects model and heterogeneity examined via χ test and I statistics. A total of 10 studies including 4,493 CF-LVAD recipients were included in the analysis (23.5{\%} women). The overall rate of stroke was significantly higher in women (odds ratio [OR] 1.94; 95{\%} confidence interval [CI] 1.32-2.84; p = 0.0007). This was true for ischemic strokes (OR 2.03; 95{\%} CI 1.21-3.42; p = 0.008) and hemorrhagic strokes (OR 2.03; 95{\%} CI 1.21-3.42; p = 0.008). Women were also more likely to develop right HF necessitating right ventricular assist device (RVAD) implantation (OR 2.12; 95{\%} CI 1.08-4.15; p = 0.03). Other adverse events including renal failure, bleeding, and device-related infection were comparable for both genders. The overall mortality while on CF-LVAD was similar in both groups (OR 1.05; 95{\%} CI 0.81-1.36; p = 0.71). Our analysis suggests that women are at greater risk of significant complications such as cerebrovascular events and right HF necessitating RVAD after CF-LVAD implantation. Further research is needed to better understand the mechanisms underlying these sex-specific outcome disparities.",
author = "Vanessa Blumer and Rodrigo Mendirichaga and Hernandez, {Gabriel A.} and Gerardo Zablah and Sandra Chaparro",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/MAT.0000000000000695",
language = "English (US)",
volume = "64",
pages = "440--449",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices

T2 - A Systematic Review and Meta-analysis

AU - Blumer, Vanessa

AU - Mendirichaga, Rodrigo

AU - Hernandez, Gabriel A.

AU - Zablah, Gerardo

AU - Chaparro, Sandra

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Continuous-flow left ventricular assist devices (CF-LVADs) decrease mortality and improve quality of life in patients with advanced heart failure (HF). Their widespread utilization has led to concerns regarding increased adverse effects, especially in women. Nevertheless, sex-specific data remain limited. We searched Medline, Embase, Scopus, and the Cochrane Library for publications reporting sex-specific outcomes after CF-LVADs from January 2008 through January 2017. Outcomes were compared under the random-effects model and heterogeneity examined via χ test and I statistics. A total of 10 studies including 4,493 CF-LVAD recipients were included in the analysis (23.5% women). The overall rate of stroke was significantly higher in women (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.32-2.84; p = 0.0007). This was true for ischemic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008) and hemorrhagic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008). Women were also more likely to develop right HF necessitating right ventricular assist device (RVAD) implantation (OR 2.12; 95% CI 1.08-4.15; p = 0.03). Other adverse events including renal failure, bleeding, and device-related infection were comparable for both genders. The overall mortality while on CF-LVAD was similar in both groups (OR 1.05; 95% CI 0.81-1.36; p = 0.71). Our analysis suggests that women are at greater risk of significant complications such as cerebrovascular events and right HF necessitating RVAD after CF-LVAD implantation. Further research is needed to better understand the mechanisms underlying these sex-specific outcome disparities.

AB - Continuous-flow left ventricular assist devices (CF-LVADs) decrease mortality and improve quality of life in patients with advanced heart failure (HF). Their widespread utilization has led to concerns regarding increased adverse effects, especially in women. Nevertheless, sex-specific data remain limited. We searched Medline, Embase, Scopus, and the Cochrane Library for publications reporting sex-specific outcomes after CF-LVADs from January 2008 through January 2017. Outcomes were compared under the random-effects model and heterogeneity examined via χ test and I statistics. A total of 10 studies including 4,493 CF-LVAD recipients were included in the analysis (23.5% women). The overall rate of stroke was significantly higher in women (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.32-2.84; p = 0.0007). This was true for ischemic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008) and hemorrhagic strokes (OR 2.03; 95% CI 1.21-3.42; p = 0.008). Women were also more likely to develop right HF necessitating right ventricular assist device (RVAD) implantation (OR 2.12; 95% CI 1.08-4.15; p = 0.03). Other adverse events including renal failure, bleeding, and device-related infection were comparable for both genders. The overall mortality while on CF-LVAD was similar in both groups (OR 1.05; 95% CI 0.81-1.36; p = 0.71). Our analysis suggests that women are at greater risk of significant complications such as cerebrovascular events and right HF necessitating RVAD after CF-LVAD implantation. Further research is needed to better understand the mechanisms underlying these sex-specific outcome disparities.

UR - http://www.scopus.com/inward/record.url?scp=85053820219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053820219&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000695

DO - 10.1097/MAT.0000000000000695

M3 - Article

C2 - 29084066

AN - SCOPUS:85053820219

VL - 64

SP - 440

EP - 449

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 4

ER -